Please login to the form below
Almirall
This page shows the latest Almirall news and features for those working in and with pharma, biotech and healthcare.
Almirall set to participate in Innovative Medicines Initiative’s FACILITATE project
Almirall also contributes its knowledge in the specification of clinical trial use cases, stakeholder requirements and the development of end-user tools. ... Commenting on the plans, Diego Herrera, Almirall’s FACILITATE project leader, said: “The
Latest news
-
Almirall granted EMA approval for lebrikizumab in atopic dermatitis
Almirall’s lebrikizumab has been granted approval by the European Medicines Agency (EMA) for its filing of a Marketing Authorization Application (MAA) for use as a treatment in patients with ... Upon approval by the EMA, patients with AD would have a
-
Almirall launches call on AlmirallShare to find innovative therapies for skin diseases
Almirall has made a seventh call via its AlmirallShare platform for new proposals to initiate collaborations in dermatological research. ... Almirall’s open innovation R&D platform has gained the attention of over 1, 100 scientists and has subsequently
-
Happify Health and Almirall launch Claro to support psoriasis patients
Almirall and Happify Health, the Intelligent Healing Company, have announced that its digital programme Claro is live and is now available to people living with psoriasis in the UK, Spain and ... Dr Volker Koscielny, chief medical officer of Almirall said
-
Almirall shares positive topline results from atopic dermatitis trials
Almirall has revealed topline results from its one-year analysis of the efficacy and safety of its investigational IL-13 inhibitor, lebrikizumab, to treat patients with moderate-to-severe atopic dermatitis ... AD). While Almirall holds the licence to
-
Almirall launches Actinic Keratosis Global Day during Skin Cancer Awareness Month
Almirall, a biopharma specialising in skin health, has unveiled the first Actinic Keratosis Global Day in partnership with Euromelanoma and AEDV Fundación Piel Sana. ... Within this particular branch of the campaign, Almirall has produced the
More from news
Approximately 20 fully matching, plus 65 partially matching documents found.
Latest Intelligence
-
Deal Watch March 2017
12. Symatese. Almirall. Development collaboration. Customised products in aesthetics. 8. AgaImmune.
-
Deal Watch December 2016
510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... $21m plus $80m equity. Biosimilars. Nuevolution. Almirall. $453m. $11.8m. Inhibitors to transcription
-
Deal Watch October 2016
$575m. $198m. 2.9. Respiratory 2014. Almirall. Products pipeline. $2, 100 milestones.
-
Deal Watch July 2016
Celyad. $311m. $12.5m. Almirall. Patagonia. $28m. $3.5m. Petra Pharma. Sprint BioScience. ... Almirall's initial expenditure has been a more modest $3.5m for this earlier stage product.
-
Stronger together
Also speaking at the eyeforpharma conference was Almirall's CEO Eduardo Sanchiz, who noted that, while patient-centricity is often talked about in the industry, “we have difficulties putting it in
More from intelligence
Approximately 2 fully matching, plus 10 partially matching documents found.
Latest appointments
-
New hires at Crescendo, Healx and Galecto
Before that, he lead global R&D at Almirall, which involved 500 staff and the development and approval of several new drugs in a number of therapy areas.
-
Almirall appoints Peter Guenter as its CEO
Together with my team, I am convinced we will be able to fully unlock the value of Almirall.”. ... I am convinced he will bring what is needed to develop Almirall to the next level.”.
-
Ron Menezes joins Almirall’s Aqua Pharmaceuticals
Pfizer. Eduardo Sanchiz, chief executive officer at Almirall, said: “We are very pleased to announce the appointment of Ron Menezes as the new president and GM of Aqua Pharmaceuticals. ... Sanchiz added: “Almirall continues to consider Aqua as a very
-
ThermiGen appoints Vladimir Paul-Blanc as president
He will also serve as the Almirall-owned firm's general manager. Medical aesthetics technology firm ThermiGen has appointed Vladmir Paul-Blanc as its president and general manager. ... He said: “I couldn’t be more excitied to join Almirall and work
-
Caldan Therapeutics bolsters senior team
Most recently, Dr Connolly served as scientific leader with Almirall, based in Barcelona, Spain.
More from appointments
Approximately 5 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
EPG Health
21Grams, Almirall, Alnylam, Amicus Therapeutics, AstraZeneca, Biogen, Boldscience, Caudex, Clinical Thinking, Convatec, CSL Behring, EMD Serono, GSK, Havas Lynx Group, In Vivo Academy, Ipsen, Janssen, Lupus UK, Merck, Novartis, Philips, Pfizer,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- ASH 2022: bad blood but big advances
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Eli Lilly announces $450m investment in US manufacturing site
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Creabilis names Catherine Moukheibir as chairman of the board
- World Health Organization releases latest set of COVID-19 guidelines
- AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
PMHub
KVA
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
